VSIG IgG Superfamily Members: Potential New Immunotherapeutic Drug Targets

The B7 family and other T cell co-stimulatory/co-inhibitory molecules are widely recognized as therapeutic targets for cancer immunotherapy. V-Set and Immunoglobulin domain containing (VSIG) proteins are members of the immunoglobulin protein superfamily and are increasingly recognized as potential immuno-oncology targets. In fact, R&D Systems scientists have identified VSIG3 as the ligand of VISTA-PD-1H.¹ Other unpublished results from our in-house research provide further evidence that the VSIG family plays an important role in T cell regulation.

R&D Systems exclusively offers bioactive VSIG proteins in both unlabeled and biotinylated formats for identifying binding partners and the development of novel therapies for immune checkpoint blockade.

References

1. Wang, J. et al. (2019) Immunology. 156:74. https://pubmed.ncbi.nlm.nih.gov/30220083.

View other Immune-checkpoint blockade targets

• Non-Human Primate Recombinant Proteins
• Avi-tag Biotinylated Proteins
• Butyrophilins
• AMIGOs
• LILRA/B Receptors
• B7/CD28 Family
• CEACAM
• VSTM

Related Pathways

T Cell Co-Signaling Pathway: Ligand-Receptor Interactions

Mechanisms of Regulatory T Cell-Mediated Suppression

Other immune-checkpoint blockade resources:

• Current and Emerging Immune Checkpoint Targets for Immuno-Oncology Research eBook
• Immune Checkpoint
• Immune Checkpoint Blockade: Immune Checkpoint Molecule Expression
• Immune Checkpoint Blockade: Immune Cell Phenotyping and Isolation
• VSIG8 Poster: Co-inhibitory Immune Checkpoint Molecule
• Immunotherapy
• A Role for VSIG-3/VISTA Signaling in Acquired Resistance to Anti-PD-1 Therapy?

All proteins from R&D Systems

• Recombinant Proteins
• Good Manufacturing Practices (GMP)-grade Proteins
• Custom Protein Services